Biotech Upcoming data

Quarter 3 2019

Ticker Phase Drug Notes Data Results
BLRX 2b BL-8040 Interim data 2h 2019
CAPR 2 HOPE-2 interim data early Q3
CARA 2 Oral KORSUVA For treatment of pruritus in stage III. top-line data in 2H of 2019.
CARA 3 KORSUVA injection For Chronic Kidney Disease-Associated Pruritus. Data expects 2H 2019.
CNCE 2 CTP-543 for treatment of moderate-to-severe alopecia areata.
DRRX 2a DUR-928 for Psoriasis data second half of 2019.
GLYC 3 RESET Patient enrollment completed in May 6.
ITCI 3 Lumateperone for neuropsychiatric and neurodegenerative diseases. Study 401 and Study404 Data failed
NTRP 2 Bryostatin Data anticipated in Q3 For Alzheimer's disease
SLGL 3 Epsolay op-line results in papulopustular rosacea in mid-2019.
SUPN 3 P301+302 for SPN-80 Data anticipated in 2H 2019
SYBX 1b/2a SYNB1618 For study in patients with PKU. data P1/2a in 3Q.
URGN 2b UGN-102 Initial data from the OPTIMA II trial of UGN-102 is expected in 2H 2019

Quarter 2 2019

Ticker Phase Drug Notes Data Results
ACHN 2 ACH-4471 Interim data to be released in May 2019 reports positive interim data for ACHN-4471
ALBO 2 A4250 data in childen with Alagile syndrome and biliary astresia at EASL, April 12. data update April 12.
ARDS 2 AR-105 data mid-2019
ASMB 2a ABI-H0731 combination studies in HBV patients expected Q2. Data update April 13.
ATRA 3 ATA 129 tab-cel® (tabelecleucel) tudies for patients with Epstein-Barr virus associated post-transplant lymphoproliferative disease (EBV+ PTLD
AXSM 3 STRIDE-1 AXS-05 in TRD, defined as major depressive disorder which has failed to respond to two or more antidepressant treatments.
AXSM 2 AXS-05 For Smoking Cessation, data anticipated 2Q 2019 Data achieves primary endpoint.
BCRX 3 APeX-2 24-week safety and efficacy data of once-daily oral BCX7353 for prophylaxis of hereditary angioedema (HAE) attacks on-track for Q2 2019 Data failed
CARA 3 KALM-1 Top-line data in 2Q 2019 positive data
CBAY 2b Seladepar magnetic resonance imaging using the proton density fat fraction method (MRI-PDFF. Study for NASH.
CDTX 2 STRIVE six poster presentations include new analyses from clinical trial of rezafungin
CNAT 2 ENCORE-LF For Liver Function clinical trial, data expected in mid-2019 Data failed
CYTK 2 FORTITUDE-ALS Date expected in Q2 2019 did not meet primary endpoint
FGEN 3 MACE djudication procedures from our roxadustat Phase 3 studies for the NDA and MAA are expected to be completed in the first half of 2019 announces positive topline results
GLYC 3 GMI-1070 continued to enroll patients with sickle cell disease (SCD) in its Phase 3 clinical trial of rivipansel for the treatment of vaso-occlusive crisis (VOC) and reports that the trial remains on track to be completed in early 2019.
GWPH 3 EPIDIOLEX trial in Tuberous Sclerosis Complex data expected Q2.
IFRX 2b SHINE Moderate or severe Hidradenitis Suppuratvia (HS). fail data
IRWD IIIb Linaclotide IBS-C patietns with data expected in mid-2019 Announced positive data.
MYOV 3 Relugolix the LIBERTY 1 trial are expected in the second quarter of 2019. in women with heavy menstrual bleeding associated with uterine fibroids. Positive data
NERV 2b MN-101 schizophrenia, major depressive disorder and insomnia disorder Five key data readouts expected in mid-2019.
NTEC 3 ACCORDANCE Clinical trial of AP-CD/LD global enrollment completed as of Feb 27, data may be in 2Q.
OCUL 3 OTX-TP Data expected in first half 2019. Data failed
SVRA 3 IMPALA study top line results expected end of Q2 2019. fail data
SYBX 1b/2a SYNB1020 in patients with cirrhosis and elevated blood ammonia expected by mid-year
TCON 3 TAPPAS trial of TRC105 in angiosarcoma interim data expected in April Data failed
TOCA 3 Toca-5 second interim analysis expected in 2Q of 2019. Data failed
VTGN 2 AV-101 For Major Depressive Disorder (MDD) Data failed

Quarter 1 2019

Ticker Phase Drug Notes Data Results
ALDX 3 RASP inhibitors Data due early Q1 success data, stock up +35.99%
ALNY 3 ENVISION Givosiran for treatment of acute hepatic porphyria data in ealry 2019 Positive topline.
ALXN 3 ALXM210 Atypical Hemolytic Uremic Syndrome (aHUS. data expected early 2019 data success
APTX 2 NYX-2925 In subjects with painful diabetic peripheral neuropathy. Data Q1 did not meet primary endpoint
ARGX 2 argx-113 data due 1H 2019
AUPH P2 Voclosporin data in Jan 2019 trial did not meet primary endpoint
AXSM 3 AXS-05 resistant depression data
AXSM 2 ASCEND trial AXS-05 MDD Success data, +161.22%
AZN 3 LYMPARZA data in 2019
BLPH 2a Cohort top-line data anticipated in 2019 Data update 1/7
CANF 2 Namodenoson for the treatment of Liver Diseases did not meet primary endpoint
CYTK 2 FORTITUDE-ALS Top-line first of 2019
FCSC 2 FCX-007 for recessive dystrophic epedemolysis bullosa Mixed data .
GILD 3 NASH and RA Data readout in Q1 data fail
GLPG 3 FINCH1 clinical data in 2019 Positive data
ICPT 3 REGENERATE Obeticholic acid (OCA) in nonalcoholic steatohepatitis (NASH) Report positive data
IMGN 3 FORWARD trial of mirvetuximab soravtansine 1h 2019 data failed
MDWD 3 NexBrid for severe burn endpoint met.
NVAX 2 NanoFlu Prgoram ResVax and NanoFlu program both data expected in Q1 data updated 1/3
ONCS 2 TAVO preliminary data
OPNT 2 OPNT001 data in Q1 did not meet primary endpoint
PIRS 2a PRS-080 half life optimized hepcidin antagonist for anemia
PRTO 3 PATENCY-2 For treatments in patients with chronic kidney disease (CKD) fail data
SAGE 3 SAGE217 data January data meet endpoints, stock +42.68%
SBBP 3 LOGICS data was scheduled for Q4 2018
SGEN 2 EV201 Top-line Data from Enfortumab Vedotin Pivotal Trial in Metastatic Urothelial Cancer Expected in the First Quarter of 2019 positive topline data
SLGL 3 SOL-GEL Epsolay and TWIN in 2019
SNNA 3 SNA-001 Topical Phtoparticle Therapy, top-line data in late Jan or early Feb
SUPN 3 P304 Novel non stimulant for the treatment of ADHD. Data expected end of Q1 of 2019. Mixed ADHD data
URGN 2b UGN-102 Initial data from trial is expected in 1H 2019. In treatment with LG Non-Muscle Invasive Bladder Cancer
UROV 3 Vibegron for Overactive bladder, data due in March 2019
VRTX 2 VX-150 Neuropathic pain primary endpoint met.
ZFGN 2 ZGN-1061 proof-of-concept trial results ealry 2019

Quarter 4 2018

Ticker Phase Drug Notes Data Results
ACRS 2 ATI-502 data end of year data update 12/17
ALDX 3 Reproxalap Allergic conjunctivitis data end of quarter or 1Q '19
ALKS 3 ALKS 3831-ENLIGHTEN-2 Top-line results (fall)
AVEO 3 TIVO-3 due to slower enrollment, data is now in Q4 announced 'positive' result. Stock fall -20.08%
BHVN 2 Trigriluzole Top-line data achieved significance on co-primary endpoitns.
BLPH 3 INOvation-1 pulmonary arterial hypertension (PAH), with top-line data for the complete study anticipated around the end of the year
CMRX 2 CMX001 IV Brincidofovir for treatment of Viral infections
CMTA 3 MOVE trial evaluating palovarotene. Fibrodysplasia
FOMX 3 FX 2016-11 and FX2016-12 topical minocycline foam 1.5%, for the treatment of rosace. Top-line early fourth quarter.
FOMX 3 FX2016-11 and FX2016-12 evaluating the safety and efficacy of FMX103, topical minocycline foam 1.5%, for the treatment of papulopustular rosacea. Top-line results are expected early in the fourth quarter of 2018. report positive data
GILD 2 GS-9674 Clinical data end of year. Liver diseases
GLPG 3 FINCH 2 Topline data 2H 2018
GTHX 2a trilaciclib triple-negative breast cancer. trilaciclib for patients undergoing chemotherapy, are expected in the fourth quarter of 2018. preliminary result at #SABCS18
GTXI 2 ASTRID Top-line result expected early Q4 trial did not meet primary endpoint. 9/21
KPTI 2b SADAL for the treatment of patients with relapsed or refractory DLBCL
KURA 2 Tipifarnib data from multiples phase 2 tipifarnib in solid tumor and hematologic Stock down -18.85% after data update at #ESMO
MNLO 2 Seropitant Data in Refractory Chronic Cough Expected in Oct 2018. Data failed
MNLO 2 Pruritus associated with psoriasis data in December
MRNS 2 Intravenous (IV) ganaxolone Report top-line P2 Magnolia study in women with PPD Data updated 12/10/18
MRNS 2 MAGNOLIA Report top-line oral ganaxolone data from Amaryllis study in women with moderate PPD fourth quarter 2018 data updated 12/4/18
NOVN 2 SB206 Viral infections data
OBSV 3 IMPLANT 2 Clinical trial of nolasiban in IVF. Also P2a PRLONG Safety, tolerability and pharmacokinetics in pregnant women, and interim efficacy .
OPHT 2a Zimura In April 2018, complete patients enrollments. Evaluate data at six months.
PBYI 2 CONTROL Top-line data data update 12/17
PRTO 3 PATENCY-2 data Q1 '19 and possibly late '18
PULM 2a PUR1800 for COPD
QURE 2b AMT-061 in hemophilia B by end of year
SBBP 3 COR-003-LOGICS Topline data
SRRA I/II SRA737 Interim data
SYBX 1b/2a SYNB1020 In development for the treatment hyperammonemia. Data end of 18
SYRS 2 SY-1425 Expect to Report Initial Data from Combination Arms Data updated, stock up 10.28% on news.
TCON 3 TRC105 interim analysis from the Phase 3 pivotal TAPPAS trial of TRC105 in angiosarcoma is expected in the second half of 2018.
UTHR 3 FREEDOM-EV clinical data
VKTX 2 VK2809 data from P2 fatty liver and hypercholesterolemia data 2H 2018 early data on Sep 18, Stock popped +87.30%
VNDA 2 Tradipitant for gastroparesis (gastroenterology) data end of year. met primary endpoint, stock +25.68%
VTVT 3 STEADYFAST- Part B data late 2018
XNCR 2 XmAb®5871 Systemic Lupus Erythematosus (SLE).

Quarter 3 2018

Ticker Phase Drug Notes Data Results
ALDX 2 and 3 Reproxalap Ocular Phase 3 Allergic Conjunctivitis , P2b Dry Eye Disease, P3 Noninfectious Anterior Uveitis and P3 sjogren-Larsson Syndrome. All expected second half 2018 positive P2 dry eye data
ALNY 3 ENVISION interim analysis mid-2018. Givosiran (Acute Hepatic Porphyrias) positive data
AMRN 3 REDUCE-IT Topline results expected to be available before the end of Q3 2018 RDUCE-IT meets primary endpoint
ANAB 2a ANAB020 in Eosinophilic Asthma Expected in the Third Quarter of 2018 positive data
ARGS 2 AGS-004 interim data due 2h 2018
ARNA 2 Olorinab study in pain associated with Crohn's disease report 'positive' results
ATNX 3 Oraxol KX-ORAX-001 second inerim analysis in 3Q 2018
ATXI 3 IV tramadol for management of moderate to moderately severe postoperative pain in patients following bunionectomy surgery.
AXON 2 Nelotanserin REM Behavior Disorder in subject with LBD
AXSM 2 AXS-05 ASCEND study for major depressive disorder (MDD). Top-line results 2H '18
BLPH 3 PAH INOvation-1 The company continues to expect the readout of interim analyst in mid-2018. DMC recommends stopping Phase 3.
BYSI 3 Piabulin Interim P3 mid-2018
CANF 2 Namodenoson Namodenoson in the treatment of heaptacellular carcinoma (HCC) expected later in 2018
CTIC 3 PIX306 trial of PIXUVRI, top-line results are expected 2Q PIXUVRI did not meet endpoint
EIGR 2 Exendin 9-39 IN PBH Exedin 9-39 phase 2 PREVENT study, and Ubenimex in Lymphedema; phase 2 ULTRA study completion. Phase 2 PREVENT announce positive result
ENTX 2 PTH (1-34) and NatPar Complete the first part of Phase 2 in Aug 1, data in coming months. Hypoparathyroidism
ESPR 3 Bempedoic Acid Global pivotal P3 study 2 52 weeks LDL-C
FLKS 2b COMMEND trial FLXS-787 Topline 3q 2018 Discontinue trial
FOMX 3 FX2017-22 he Company’s minocycline foam 4%, in patients with moderate-to-severe acne. Positive late stage data
GALT 2 KEYTRUDA enroll cohort 3 (GR-MD-02 8 mg/kg) of the pembrolizumab (KEYTRUDA) combination immunotherapy clinical trial, data mid-2018
GERN 2 IMbark Geron expects Janssen to inform the Company of its decision by the end of the third quarter of 2018. Discontinuation Imetelstat
GLPG 3 FINCH 2 Expect FINCH 2 results in 3Q Data meets primary endpoint
IONS 2 AKCEA-APO(a)-LRx and AKCEA-ANGPTL3-LRx six Phase 2 programs throughout 2018
OBSV 2B OBE2109 due mid 2018
OMER 2 OMS721 Immunoglobulin A (IgA) nephropathy. Mixed data result
ONCE I/II Hemophila A- SPK-8011 investigational gene therapy
ONCS 2b PISCES/KEYNOTE-695 Dosing of first patient on Dec 14, 2017. data in 2018. (No specific quarter given)
OVID 2 OV101- STARS Enrollment i n STARS trial to adolescent Angelman syndrome. Trial to be available 2H 2018 Positive data, but investors concerned stock -36.55% for the day.
PBYI 3 PB272 (neratinib) third-line metastatic breast cancer patients in the second half of 2018
RARE 2 Crysvita (burosumab) his is an open label Phase 2 study evaluating the safety and efficacy of burosumab in 17 adult patients with TIO.
RDHL 3 RHB-104 Topline data Primary endpoint successfully achieved.
RYTM 2 setmelanotide Studies of setmelanotide in BBS and Alstrom Syndrome. Sept 27-29 data.
SCYX 2b SCY-078 Topline data by July positive results oral SCY-078
SPPI 2 Poziotinib Breast Cancer. Data possibly release in fall Updated data on September 24
TGTX 3 UNITY-CLC Top-line ORR and relapsed/refractory Chronic Lymphocytic Leukemia (CLL). DSMB trial ORR cannot be conducted.
TNXP 3 HONOR study of Tonmya Interim Analysis 3Q 2018;Topline results expected in 3Q 2018 discontinue Phase 3 HONOR
TORC 2b TORC1 top-line 16 weeks data expected 3Q. trial is designed to evaluate the safety, tolerability and efficacy of RTB101, an orally-administered selective TORC1 inhibitor, announces 'positive' P2b RTB101
URGN 3 OLYMPUS topline data
VTL 3 VTL-308 ELAD System in subjects with severe alcoholic hepatitis (sAH). Clinical data in second half of September 2018 Data failed
ZGNX 3 ZX008 Second pivotal trial Phase 3 Dravet syndrome program, STUDY 1504. Data late June-early July. Primary endpoint achieved

Quarter 2 2018

Ticker Phase Drug Notes Data Results
ACRS 2 AT-50002 Topical Top-line data 1H 2018 positive interim data
ALXN 3 PREVENT and ALXN210 Data mid-2018. Eculizumab- Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD) Success
AQXP 3 AQX-1125 LEADERSHIP data Failed to meet primary endpoint
AXSM 3 STRIDE-1 trial of AXS-05 IN TRD, top-line data 1H 2018
BMRN 2 Hemophilia A update on the ongoing Phase 2 program with valoctocogene roxaparvovec at the World Federation of Hemophilia 2018 World Congress. May 20-24 Data were updated at World Congress
CLDX 2b METRIC Topline data likely Q2 2018 Data failed
CLSD 2 TYBEE Patients follow-up six months data -32.19% Stock reaction to 'positive' data.
EDGE 3 EG-1962 Interim-topline data data failed
ESPR 3 ASCVD and/or HeFH Statin add on Global pivotal P3 study 1, 52 weeks long term safety. Company press 'positive' data, but safety concerns dropped stock -35.11%.
FOMX 3 FMX103 Topline data mid 2018
GBT 3 HOPE study Top -line clinical data by end of quarter Primary endpoint achieved
GEMP 2B INDIGO-1 Top-line data Meet primary endpoint
GLMD 2b ARREST Phase IIB data late Q1 or early Q2 2018. Data update stock up +151.29%
GNMX 2 AEVI-001 Phase 2 (ASCEND) for patients with ADHD. Data expected mid-2018
HRTX 2 HTX-011 data likely late Q2 for kneee arthroplasty positive topline results. Stock up +30.13%
IDRA 2 IMO-8400 Topline data in June miss primary endpoint
INCY 3 ECHO-301 Initial results of the ECHO-301 trial of epacadostat in melanoma and REACH 1 trial of ruxolittinib in acute GVHD Data failed
IONS P1/2a IONIS-SOD1 ALS Topline Data Mid Q2
JNCE 1/2 ICONIC Preliminary Efficacy data in the first half of 2018 Underwhelming abstract, stock -35.20% reaction
KPTI 2 STORM April data Positive Phase 2a
MDGL 2 MGL-3196 Final 36-week data, top line results by end of May MDGL-3196 Achieves Endpoints
MNLO 2 ATOMIK atopic dermatitis data expected April 2018 Data failed
NBRV 3 LEAP 2 Data are expecting in Spring 2018 Company press lefamulin meets all primary endpoints. Stock down -16.57%
PRTA IIb NEOD1 Top-line data Data failed, stock down -68.78%
SBBP 3 RECORLEV Top-line results on track with SONICS Positive results.
SELB 2 SEL-212 Symtomatic Gout Patients. Updated Clinical data at PANLAR Congress on Tuesday, April 10, 2018
VICL 2 HSV-2 Therapeutic Vaccine trial vaccine did not meet primary endpoint
VTVT 3 STEADFAST STEADFAST study (azeliragon in Alzheimer's disease) Part A early 2018 Data failed
XLRN 3 MEDALIST and BELIEVE Data mid 2018 Achieved primary and secondary endpoints

Quarter 1 2018

Ticker Phase Drug Notes Data Results
ACOR 3 Tozadenant Phase 3 data
AIMT 3 PALISADE "Anticipate sharing topline in first quarter 2018"
ANTH 3 Sollpura-RESULT data due end of Q1
ARGX 2 ARGX-113 Myasthenia gravis data
AXON 2 Intepirdine and Nelotanserin January data: HEADWAY in patients with dementia with Levy bodies (DLB). subjects with Alzheimer's disease, DLB and Parkinson's disease dementia (PDD). Nelotanserin (LBD).
AXSM 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis
BLPH 3 INO pulse for PAH indication Topline line data
BOLD 1/2 AT132 Phase 1/2 data readout of AT132 XLMTM
Cidara Therapeutics Inc (CDTX) 2 STRIVE completing enrollment of the 90-patietn. P2 Rezafungin
CLSD 3 PEACHTREE Macular Edema Associated with Non-infectious Uveitis, top line data.
CPRX 2 CMS-001 Expect top-line results from CMS-001 in first half 2018
DERM 3 CLAREOS 1 and CLAREOS 2 October 5, 2017 completes patient enrollment in Two Phase 3 pivotal trials of Olumacostat Glasaretil for the treament of Acne Vulgaris. Topline.
EARS 3 KEYZILEN P3 TACTT3 topline data
EIGR 2 LIBERTY Ubenimex in PAH
EYEG 3 EGP-437 Topline data
FGEN 2 FG-3019 Pancreatic caner study results
FLKS 2 FLX-787 Multiples Sclerosis Readout data end of Q1
GEMP 2b INDIGO-1 top-line data
GTHX 2a trilaciclib trilaciclib first-in-line small cell lung cancer. Data in March
IDRA 2 IMO-2125 Clinical trial of 8mg intratumoral IMO-2125 in combination with ipilimumab in anti-PD1 reffractory melanoma. ORR data
MNOV 2 mn-166 Completion enrollment news on Sept 19,2017. Final data Q1
MRNS 2 CDKL5 on-going in the Magnolia Study, with data expected in early 2018
OVID 2 STARS Sometimes 2018
PTGX 2b PTG-300 interim analysis early 2018
REGN 3 Praluent ODYSSEY OUTCOMES Cardiovascular events.
TCON 2 TRAXAR trial of TRC105 Top-line data from the randomized P2
TRPX IIa THX-110 Tourette syndrome. Top-line anticipated in first half 2018
TTPH 3 IGNITE3 Additional data
VBLT 3 VB-111 top-line results
VICL 3 ASP0013 The multinational phase 3 registration trial in HCT recipients completed enrollment in Sept 2016 with a total 515 subjects.
VRTX 2 VX-445 and VX-659 triple combinations in CF patietns data 1H18
VTGN 2 AV-101 P2 monotherapy study completion expected early 2018
VTVT 3 STEADFAST STEADFAST study (azeliragon in Alzheimer's disease) Part A early 2018 Data failed

Quarter 4 2017

Ticker Phase Drug Notes Data Results
ADRO 2 CRS-207 in combination with pembrolizumab Report early observations from the ongoing phase 2 mesothelioma study
AGLE 1 AEB1102 Potential data end of year.
ARDX 3 T3MPO-2 Results of Tenapanor for IIBS-C on track early Q4
AVXL 2a ANAVEX 2-73 PK/PD data
CALA 2 CB-839 In July 2017, Calithera initiated a phase 2 trial of CB-839 with pcitaxel in triple negative breast cancer patietns.
CLDX 2 Glembatumumab Vedotin The company anticipated in fall of 2017
CNCE 2b CTP-543 End of year data
CPRX 3 Firdapse® Top-line Results expected in early December. Completes enrollment in second phase 3 trial on Oct 31,2017
DBVT 3 PEPITES to report topline results from PEPITES in October 2017
EARS 3 AM-111 HEALOS The trial enrolled 256 patients with severe to profound idiopathic sudden sensorineural hearing loss.
EIGR 2 LIMT HDV interim data study at AASLD
GALT 2b NASH-CX Clinical data in December
IRWD 2 IW-1973 data from two phase IIa studies with IW-1973 in diabetic patients with hypertension are expected by end of 2017.
KDMN 2 KD025 Randomized, open-label clinical trial in idiopathic pulmonary fibrosis
KDMN 2 KD025 Randomized, open-label clinical trial in idiopathic pulmonary fibrosis and full data to severe psoriasis
KURA 2 tipifarnib Phase 2 trial of tipifarnib in HRAS mutant SCCHN second half 2017
MDGL 2 MGL-3196 for NASH Top-line results for the primary endpoint of the trial, the reduction of liver fat, assessed by MRI-PDFF at 12 weeks, are expected by year-end
MLNT 2/3 Taksta exploratory trial data in refractory bone and joint infections.
MNOV 2b SPRINT-MS/NN 102 phase 2b Trial of Ibudilast in progressive MS has been accepted for oral platform presentation at 7th Join ECTRIMS*ACTRIMS meeting October 25-28, 2017 in Paris, France
ONTX 3 INSPIRE interim analysis anticipate in Q4
RARX 2 RA101495 Cohort B of Ra Pharma's Phase 2. The company remains on track to report additional data around year-end.
RVNC 2 RT002 RT002 injectable in management of plantar fascitis
RVNC 3 SAKURA 1&2 rt002 Injectable for the treatment of glabellar (frown) lines
SAGE 2 SAGE-217 SAGE-217 in PPD and essential tumor 2H2017
SGEN 3 ADCETRIS Full data from ADCETRIS phase 3 ECHELON-1 trial
STML 2 SL-401 In Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Top line results in 2h17
SYRS 2 SY-1425 on track to present initial phase 2 clinical data
TGTX 2 TG-1101 multiples sclerosis trial update
VKTX 2 VK5211 Phase 2 hip fractured study full enrolled, data expected Q4 '17. From Aug 19 press released

Quarter 3 2017

Ticker Phase Drug Notes Data Results
ABBV 3 SELECT-BEYOND top-line data likely 3Q
ABUS 2 HBV ARB1467 data
ABUS 2 ARB-1467 top-line results from the three-month bi-weekly dosing expect to be announced in September
ALDX 2A ADX-102 Clinical trial in Dry Eye Disease
ALNY 2 hempohillia Fitusiran PII OLE dadta
ALNY 3 APOLLO results for Patisiran in near term
ANTH 2 BRIGHT BRIGHT study of blisibimod in IgA
ARRY 3 BEACON CRC data from the safety due at ESMO
AXON 3 Alzheimer's disease Data to be out in September 2017
AZRX IIa MS1819 expect completion Phase IIa in 3Q
BLPH 2a PH-IPF "results of this study in near futture" -Mr. Tenenbaum
FOLD 3 SD-101 SD-101 for Epidermolysis Bullosa (EB), Top-line P3 late 3Q
GILD 2 GS-0976 NASH data
GTXI 2 Enobosarm top-line results in 3Q
INSM 3 ARIKAYCE data out in September
KDMN 2 KD025 Open-label, dose finding clinical trial in chronic graft-versus-host disease. Also Tesevatinib data
MDCO 3 Meropenem-Vaborbactam TANGO 2 end of 3Q
MRNS 2 CDKL5 Phase 2 trial evaluating children with CDKL5 disorder
NBRV 3 Infections LEAP 1 data.
OTIC 3 AVERTS-1 Phase 3 AVERTS-1 trial for OTIVDEX(tm) in September
RDHL 2 BEKINDA IBS-D data in September
SAGE 3 Brexanolone in SRSE top-line results from STATUS trial
STML 2 SL-401 top-line results in 2h17
VNDA 2 Tradipitant study for treatment of chronic pruritus in patients with atopic dermatitis.
VSAR 3 Pediatric GHD Top line from pediatric phase 3 Velocity trial around end of September
VSTM 3 Duvelisib Phase 3 DUO top-line latter part of summer
ZYNE 2 FAB-C top-line results from the FAB-C Fragile X study in September

Quarter 4 20018

Ticker Phase Drug Notes Data Results
FGEN 3 Roxadustat topline data for anemia in chronic kidney disease

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that TradersFish.com will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.